Literature DB >> 14532804

New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience.

Michele Spinelli1, Gianluca Giardiello, Martin Gerber, Andrea Arduini, Ubi van den Hombergh, Silvia Malaguti.   

Abstract

PURPOSE: In functional urology today chronic stimulation of the sacral nerves has become one of the most accepted methods of stimulation treatment. Many studies have described the advantage of test stimulation prior to implanting the definitive system to enable effective patient selection. We studied a method aimed at improving lead anchoring by developing a self-blocking electrode with a simple placement procedure, in the process creating a 2-stage approach to full percutaneous implantation that allows a long screening period during the first temporary stimulation stage.
MATERIALS AND METHODS: A new tined lead was specifically designed to allow minimally invasive percutaneous lead placement requiring no incision and no additional fascial anchoring. From September 2001 to November 2002, 15 consecutive patients (3 males and 12 females) 27 to 70 years old (mean age 49) underwent this procedure and were prospectively evaluated. No PNE test was performed.
RESULTS: Following the first stage screening phase 12 patients were implanted with the implantable pulse generator (IPG), while 3 who did not respond positively to test stimulation (neurogenic voiding dysfunction, urge incontinence and neurogenic urge incontinence in 1 each) did not undergo IPG implantation and had the tined lead removed under local anesthesia. We did not observe any lead displacement during the screening period (average 38.8 days) or during followup of IPG implanted cases (average 11 months, range 5 to 19).
CONCLUSIONS: Our results show that the new tined anchoring system is a reliable way to allow truly minimally invasive placement of the chronic lead.

Entities:  

Mesh:

Year:  2003        PMID: 14532804     DOI: 10.1097/01.ju.0000092634.64580.9a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  34 in total

Review 1.  Managing nocturia.

Authors:  Serge P Marinkovic; Lisa M Gillen; Stuart L Stanton
Journal:  BMJ       Date:  2004-05-01

Review 2.  Sacral neuromodulation for lower urinary tract dysfunction.

Authors:  Philip E V Van Kerrebroeck; Tom A T Marcelissen
Journal:  World J Urol       Date:  2011-10-12       Impact factor: 4.226

Review 3.  Sacral neuromodulation and female sexuality.

Authors:  Giuseppe Lombardi; Enrico Finazzi Agrò; Giulio Del Popolo
Journal:  Int Urogynecol J       Date:  2015-04-16       Impact factor: 2.894

4.  New tined lead electrode in sacral neuromodulation: experience from a multicentre European study.

Authors:  Michele Spinelli; Ernest Weil; Edoardo Ostardo; Giulio Del Popolo; José L Ruiz-Cerdá; Gustav Kiss; John Heesakkers
Journal:  World J Urol       Date:  2005-06-30       Impact factor: 4.226

Review 5.  [Neurourology. Current developments and therapeutic strategies].

Authors:  J Kutzenberger; J Pannek; M Stöhrer
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

Review 6.  Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain.

Authors:  Robert D Mayer; Fred M Howard
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

7.  Sacral nerve stimulation for constipation: do we still miss something? Role of psychological evaluation.

Authors:  Alfonso Carriero; Jacopo Martellucci; Pasquale Talento; Carlo Andrea Ferrari
Journal:  Int J Colorectal Dis       Date:  2010-02-17       Impact factor: 2.571

Review 8.  Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.

Authors:  Samina Tahseen
Journal:  Int Urogynecol J       Date:  2018-01-04       Impact factor: 2.894

Review 9.  Fowler's syndrome--a cause of unexplained urinary retention in young women?

Authors:  Nadir I Osman; Christopher R Chapple
Journal:  Nat Rev Urol       Date:  2013-12-10       Impact factor: 14.432

10.  Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability.

Authors:  Tanya Davis; Iryna Makovey; Michael L Guralnick; R Corey O'Connor
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.